4.6 Article

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

期刊

EUROPEAN JOURNAL OF ENDOCRINOLOGY
卷 152, 期 2, 页码 269-275

出版社

BIOSCIENTIFICA LTD
DOI: 10.1530/eje.1.01840

关键词

-

向作者/读者索取更多资源

Objective: Women with polycystic ovary syndrome (PCOS) exhibit risk factors for cardiovascular diseases such as abdominal obesity, insulin resistance and dyslipidemia. Insulin sensitizers, especially metformin, have been shown to improve these metabolic disturbances, but there are only a few studies on their effects on serum lipids in polycystic ovary syndrome. Methods: Thirty-five women with PCOS (18 obese and 17 non-obese) were randomized to 6-month treatments with metformin or ethinyl estradiol-cyproterone acetate oral contraceptive pills. Results: In the whole-study population (non-obese and obese women) serum levels of high-density lipoprotein cholesterol increased from 1.4 +/- 0.2 to 1.6 +/- 0.1 mmol/l (means +/- S.E. throughout) at 3 and 6 months (P < 0.001), the total cholesterol:high-density lipoprotein cholesterol ratio decreased significantly from 3.8 +/- 0.3 to 3.3 +/- 0.2 at 6 months (P < 0.001) and a similar trend was observed in serum triglyceride levels during metformin treatment. In the oral contraceptive group, serum levels of total cholesterol increased from 4.9 +/- 0.3 to 5.4 +/- 0. 3 mmol/l (P < 0.05), high-density lipoprotein cholesterol increased from 1.2 +/- 0.1 to 1.5 +/- 0.1 mmol/l (P < 0.001), the total cholesterol: high-density lipoprotein cholesterol ratio decreased from 4.6 +/- 0.4 to 3.7 +/- 0.2 (P < 0.001) and triglycerides increased from 1.3 +/- 0.1 to 1.9 +/- 0.2 mmol/l at 6 months of treatment (P < 0.001). Serum low-density lipoprotein cholesterol levels remained unchanged during both treatments. Milder but similar changes in the subgroups of obese and non-obese women were observed during both treatments. Moreover, in the whole-study population both systolic (P = 0.02) and diastolic (P = 0.05) blood pressures decreased over the 6 months of metformin treatment. Conclusion: In women with PCOS, metformin treatment had beneficial effects on lipid profile and blood pressure, and therefore it could be useful in the prevention of cardiovascular complications in these women.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据